BioMarin Pharmaceutical Inc. (BMV:BMRN)
Mexico · Delayed Price · Currency is MXN | Market Cap | 167.72B -25.6% |
| Revenue (ttm) | 58.45B +9.9% |
| Net Income | 4.84B -48.7% |
| EPS | 25.18 -48.4% |
| Shares Out | n/a |
| PE Ratio | 34.62 |
| Forward PE | 8.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 75 |
| Average Volume | 171 |
| Open | 965.00 |
| Previous Close | 984.09 |
| Day's Range | 959.00 - 965.00 |
| 52-Week Range | 959.00 - 1,200.00 |
| Beta | n/a |
| RSI | 35.37 |
| Earnings Date | Jul 31, 2026 |
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA... [Read more]
Financial Performance
In 2025, BioMarin Pharmaceutical's revenue was $3.22 billion, an increase of 12.87% compared to the previous year's $2.85 billion. Earnings were $348.90 million, a decrease of -18.26%.
Financial numbers in USD Financial StatementsNews
BioMarin price target lowered to $111 from $116 at Canaccord
Canaccord lowered the firm’s price target on BioMarin (BMRN) to $111 from $116 and keeps a Buy rating on the shares. The firm updated its model following the news the…
BioMarin's drug shows significant growth gains in children in late-stage trial
BioMarin Pharmaceutical said on Wednesday its treatment for a rare condition that leads to short stature helped boost growth in children, meeting the main goal of a late-stage study and sending shar...
BioMarin’s Voxzogo meets endpoint in Phase 3 pediatric hypochondroplasia trial
BioMarin (BMRN) Pharmaceutical announced that the Phase 3 CANOPY-HCH-3 study evaluating treatment with Voxzogo – vosoritide – in children with hypochondroplasia met its primary endpoint, demonstrating...
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline) of 2.33 cm/yr compared to placebo at we...
BioMarin price target lowered to $80 from $85 at BofA
BofA analyst Jason Zemansky lowered the firm’s price target on BioMarin (BMRN) to $80 from $85 and keeps a Buy rating on the shares after the company announced the Phase…
BioMarin initiated with a Buy at Citi
Citi initiated coverage of BioMarin (BMRN) with a Buy rating and $75 price target The firm views the stock’s “dislocated” valuation as a product of “overly cautious” views on Voxzogo’s…
BioMarin price target lowered to $62 from $64 at Leerink
Leerink lowered the firm’s price target on BioMarin (BMRN) to $62 from $64 and keeps a Market Perform rating on the shares after the company provided an update on the…
BioMarin price target lowered to $50 from $55 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on BioMarin (BMRN) to $50 from $55 and keeps a Neutral rating on the shares. The company’s Phase 3 ENERGY 3 study in…
BioMarin's genetic disease therapy shows mixed results in late-stage study
BioMarin Pharmaceutical said on Monday its experimental treatment for a rare genetic condition met one of the two main goals in a late-stage study.
BioMarin’s BMN 401 meets 1 of 2 endpoints in Phase 3 ENPP1 trial
BioMarin (BMRN) announced results from the pivotal Phase 3 ENERGY 3 trial evaluating BMN 401 in children aged 1-12 with ENPP1 deficiency, a rare, serious and progressive genetic condition. Deficiency…
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency Treatment with BMN 401 led to statistically significant increases in plasma inorganic pyrophosphate (PPi) concentration...
BioMarin reinstated with a Neutral at Goldman Sachs
Goldman Sachs reinstated coverage of BioMarin (BMRN) with a Neutral rating and $69 price target following the completion of the Amicus acquisition. While the shares are trading around the value…
BioMarin price target raised to $116 from $104 at Canaccord
Canaccord analyst Whitney Ijem raised the firm’s price target on BioMarin (BMRN) to $116 from $104 and keeps a Buy rating on the shares. The firm said 1Q26 earnings delivered…
BioMarin price target lowered to $119 from $120 at Morgan Stanley
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on BioMarin (BMRN) to $119 from $120 and keeps an Overweight rating on the shares. Q1 reinforces a near-term transition…
BioMarin price target raised to $120 from $110 at Evercore ISI
Evercore ISI raised the firm’s price target on BioMarin (BMRN) to $120 from $110 and keeps an Outperform rating on the shares.
BioMarin price target lowered to $82 from $94 at Bernstein
Bernstein analyst William Pickering lowered the firm’s price target on BioMarin (BMRN) to $82 from $94 and keeps an Outperform rating on the shares. The firm notes revenue beat by…
BioMarin Pharmaceutical Earnings Call Transcript: Q1 2026
Amicus acquisition closed, boosting 2026 revenue growth outlook to 20% and expanding the portfolio with Galafold and Pombiliti/Opfolda. Strong Q1 demand for enzyme therapies and Voxzogo, especially among young children, supports raised guidance. Over half of 2026 revenues expected in H2.
BioMarin Pharmaceutical Slides: Q1 2026
BioMarin Pharmaceutical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 4, 2026.
BioMarin Pharmaceutical Earnings release: Q1 2026
BioMarin Pharmaceutical released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
BioMarin Pharmaceutical Quarterly report: Q1 2026
BioMarin Pharmaceutical has published its Q1 2026 quarterly earnings report on May 4, 2026.
BioMarin Reports First Quarter 2026 Financial and Operating Results
First Quarter 2026 Total Revenues Increased Year-over-year to $766 million Increased Full-year 2026 Total Revenues Guidance to between $3.825 billion and $3.925 billion, Representing Accelerated Growt...
BioMarin announces new research from studies of Voxzogo
BioMarin (BMRN) Pharmaceutical announced new research from studies of Voxzogo in children with achondroplasia demonstrating positive impact on important health indicators, including arm span and bone ...
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting
VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over 10 years of clinical research demonstrating the long-term benefit on complications associated with ...
BioMarin completes acquisition of Amicus Therapeutics
BioMarin Pharmaceutical(BMRN) said that it completed the previously announced agreement to acquire Amicus Therapeutics (FOLD) for $14.50 per share in an all-cash transaction for a total equity value o...
BioMarin Completes Acquisition of Amicus Therapeutics
Acquisition Adds Galafold ® (migalastat) for Fabry Disease and Pombiliti ® (cipaglucosidase alfa-atga) + Opfolda ® (miglustat) for Pompe Disease to BioMarin's Commercial Portfolio BioMarin Expects to ...